west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "尼达尼布" 2 results
  • Research progress of targeted drugs for idiopathic pulmonary fibrosis

    After pirfenidone and nintedanib showed efficacy, drug treatment for idiopathic pulmonary fibrosis began to focused on anti-fibrosis. Current research on idiopathic pulmonary fibrosis mainly focus on the pathogenesis and therapeutic targets, and more targeted drugs are gradually entering clinical trials. This article summarizes the results of recent studies on the treatment of idiopathic pulmonary fibrosis with pirfenidone and nintedanib alone or in combination by searching the literature, and reviews the mechanism and test results of the new target anti-fibrosis drugs based on molecular biology that are currently undergoing clinical research in various phases, and aims to provide a basis for how to choose drugs to treat idiopathic pulmonary fibrosis.

    Release date:2020-07-26 03:07 Export PDF Favorites Scan
  • 尼达尼布治疗放射性肺损伤一例并文献复习

    目的探讨放射性肺损伤的发病机制、临床表现、影像学特点、可能的治疗手段及预后。方法分析 1 例确诊为肺鳞癌合并放射性肺损伤并接受尼达尼布治疗患者的临床资料,结合相关文献复习,总结其临床特点、治疗过程及预后。结果本例为 72 岁男性肺鳞癌患者,经同步放化疗和放射性粒子植入术后并发放射性肺损伤,主要症状为活动后气促,胸部 CT 表现为双肺磨玻璃影和网格影,右下肺显著。经尼达尼布规范化治疗 4 个月后,临床症状以及影像学都明显缓解,随访 1 年,病情持续稳定,未见明显不良反应。文献复习发现,放射性肺损伤患者临床上多表现为干咳、发热及呼吸困难,重症患者可危及生命,影像学多表现为放射靶区的片状影,多以肺实变伴支气管充气征为主。最常用的治疗药物为糖皮质激素,也有少部分患者对激素治疗反应不佳,新的治疗手段仍在探索之中。结论放射性肺损伤是恶性肿瘤患者放疗过程中较常见的并发症,但目前治疗手段有限,尼达尼布作为一种新型的小分子靶向药,可能对放射性肺损伤具有一定的修复作用。

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content